- Home
- EU vs PLRX Comparison
EU vs PLRX Comparison
Compare EU & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EU | PLRX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.2M | 74.9M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EU | PLRX |
|---|---|---|
| Price | $1.60 | $1.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $4.00 | $2.67 |
| AVG Volume (30 Days) | ★ 2.8M | 423.4K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 29.97 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $43,155,000.00 | N/A |
| Revenue This Year | $212.11 | N/A |
| Revenue Next Year | $29.88 | N/A |
| P/E Ratio | $52.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.34 | $1.09 |
| 52 Week High | $4.19 | $1.95 |
Technical Indicators
Market Signals| Indicator | EU | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 58.14 |
| Support Level | $1.34 | $1.13 |
| Resistance Level | $2.17 | $1.37 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 65.00 | 96.55 |
Price Performance
Historical ComparisonAbout EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.